Press release
Gastritis Pipeline and Clinical Trials Assessment (2023) | Companies- Daewoong Pharmaceutical, RedHill Biopharma, Add Pharma, Allakos, Hanmi Pharmaceutical Company Limited, GC Pharma, and others
Gastritis Pipeline
The pipeline analysis report for emerging drugs in Gastritis offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Gastritis pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, clinical trial studies conducted for Gastritis, any obtained NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.
To explore more information on the latest breakthroughs in the Gastritis Pipeline treatment landscape of the report, click here @ Gastritis Pipeline Outlook- https://www.delveinsight.com/sample-request/gastritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Gastritis Pipeline Report
• DelveInsight's Gastritis Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading Gastritis Companies are working in the market include Daewoong Pharmaceutical, RedHill Biopharma, Add Pharma, Allakos, Hanmi Pharmaceutical Company Limited, GC Pharma, Daewon Pharmaceutical, Korea Otsuka Pharmaceutical, Chong Kun Dang Pharmaceutical, RedHill Biopharma Limited, Xinjiang Biochemical Pharmaceutical Co. Ltd, and others
• Promising Gastritis Pipeline Therapies in the various stages of development include RHB-102, Gastropylor Complex Capsules, Rebamipide, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg, Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg, CKD-495 75mg, Stillen Tab., Eupasidin-s Tab, DWP14012 X mg, DW1903, and others
• Neurogastrx, in June 2021, announced the signing of an exclusive license agreement with Daewoong Pharmaceutical for the development and commercialization of fexuprazan. Fexuprazan is an investigational potassium-competitive acid blocker (P-CAB) intended for the treatment of erosive esophagitis (EE) and other acid-related conditions. EE is a chronic and progressive ailment affecting a significant number of patients in the United States.
• Fexuprazan is designed to inhibit the secretion of gastric acid in the stomach by blocking proton pumps. Compared to proton pump inhibitors (PPIs), the current standard of care for EE, P-CABs have demonstrated faster and more effective and sustained suppression of acid secretion.
• RHB-102, developed by RedHill, is a proprietary oral medication formulated as a bi-modal extended-release pill with a duration of 24 hours. It contains ondansetron, an antiemetic drug that acts as a 5-HT3 receptor antagonist. RedHill successfully completed a Phase 3 study in the United States, known as the GUARD study, with RHB-102 24 mg. This study focused on patients with acute gastroenteritis and gastritis and achieved the primary efficacy and safety endpoints.
Gastritis Overview
Gastritis has its basis in histological features of the gastric mucosa. It is not erythema observed during gastroscopy, and there are no specific clinical presentations or symptoms defining it. The current classification of gastritis centers on time course (acute versus chronic), histological features, anatomic distribution, and underlying pathological mechanisms. Acute gastritis will evolve to chronic, if not treated. Helicobacter pylori (H. pylori) is the most common cause of gastritis worldwide.
For further information, refer to the detailed Gastritis Unmet Needs, Gastritis Market Drivers, and Gastritis Market Barriers, click here for Gastritis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/gastritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gastritis Emerging Drugs Profile
• Fexuprazan: Daewoong Pharmaceutical
• RHB-102: RedHill Biopharma
Gastritis Pipeline Therapeutics Assessment
There are approx. 15+ Gastritis companies which are developing the Gastritis therapies. The Gastritis companies which have their Gastritis drug candidates in the most advanced stage, i.e Phase III include, Hanmi Pharmaceutical.
Request a sample and discover the recent advances in Gastritis Ongoing Clinical Trial Analysis and Medications, click here @ Gastritis Treatment Landscape- https://www.delveinsight.com/sample-request/gastritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gastritis Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Gastritis Therapeutics Market include-
Daewoong Pharmaceutical, RedHill Biopharma, Add Pharma, Allakos, Hanmi Pharmaceutical Company Limited, GC Pharma, Daewon Pharmaceutical, Korea Otsuka Pharmaceutical, Chong Kun Dang Pharmaceutical, RedHill Biopharma Limited, Xinjiang Biochemical Pharmaceutical Co. Ltd, and others
Dive deep into rich insights for drugs for Gastritis Pipeline, click here @ Gastritis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/gastritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Gastritis Pipeline Report
• Coverage- Global
• Gastritis Companies- Daewoong Pharmaceutical, RedHill Biopharma, Add Pharma, Allakos, Hanmi Pharmaceutical Company Limited, GC Pharma, Daewon Pharmaceutical, Korea Otsuka Pharmaceutical, Chong Kun Dang Pharmaceutical, RedHill Biopharma Limited, Xinjiang Biochemical Pharmaceutical Co. Ltd, and others
• Gastritis Pipeline Therapies- RHB-102, Gastropylor Complex Capsules, Rebamipide, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg, Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg, CKD-495 75mg, Stillen Tab., Eupasidin-s Tab, DWP14012 X mg, DW1903, and others
• Gastritis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Gastritis Mergers and acquisitions, Gastritis Licensing Activities @ Gastritis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/gastritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Gastritis Executive Summary
3. Gastritis: Overview
4. Gastritis Pipeline Therapeutics
5. Gastritis Therapeutic Assessment
6. Gastritis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. HIP2101: Hanmi Pharmaceutical Company
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GC-6101A: GC Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Discovery Stage Products
17. AD 215: Addpharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Gastritis Key Companies
21. Gastritis Key Products
22. Gastritis- Unmet Needs
23. Gastritis- Market Drivers and Barriers
24. Gastritis- Future Perspectives and Conclusion
25. Gastritis Analyst Views
26. Gastritis Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastritis Pipeline and Clinical Trials Assessment (2023) | Companies- Daewoong Pharmaceutical, RedHill Biopharma, Add Pharma, Allakos, Hanmi Pharmaceutical Company Limited, GC Pharma, and others here
News-ID: 3080151 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Gastritis
Acute Gastritis Treatment Market 2022 Size & Industry Forecast by 2027
The Acute Gastritis Treatment Market research report discusses the key drivers influencing global growth, opportunities, current challenges and the risks faced by key players and the market as a whole Acute Gastritis Treatment Market competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch.
Acute Gastritis Treatment Market is…
Gastritis Treatment Market Professional Inspection Report 2020-2027
Global Gastritis Treatment Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of Gastritis Treatment Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and…
Gastritis Treatment Market: Moving Towards a Brighter Future
Global Gastritis Treatment Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of Gastritis Treatment Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and…
Gastritis Overview - Symptoms, Types, causes and Gastritis Treatment
An Overview:
Gastritis is a general term that refers to a group of conditions, each identifiable by inflammation, erosion, or irritation in the lining of the stomach. It can appear in a number of different forms, some more serious than others, and require different methods of treatment.
Whether you have gastritis or not, knowing precisely what it is, what symptoms it can cause, and how to go about treating it is important…
Atrophic Gastritis Global Clinical Trials Review, H1, 2017
"The Report Atrophic Gastritis Global Clinical Trials Review, H1, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Atrophic Gastritis Clinical Trials Market
Summary
GlobalData's clinical trial report, Atrophic Gastritis Global Clinical Trials Review, H1, 2017" provides an overview of Atrophic Gastritis clinical trials scenario. This report provides top line data relating to the clinical trials on Atrophic Gastritis. Report includes an…
Gastritis Treatment Market – Global Industry Insights 2024
Gastritis is the irritation, or inflammation, or erosion of the stomach lining. Gastritis may be acute or chronic. The disease may show some symptoms or the symptoms may be dormant. Usually, the symptoms include upper abdominal pain, nausea, and vomiting. Gastritis may lead to stomach tumors, bleeding, and stomach ulcers. Gastritis is usually caused by the bacteria helicobacter pylori or by the use of nonsteroidal anti-inflammatory drugs or NSAIDs. Other…
